MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia, and Alzheimer’s in the EU and UK MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK LONDON, April 5, 2022 /PRNewswire/ — MGC Pharmaceuticals Ltd., a European based biopharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK. (PRNewswire) The agreement is for the distribution in key European territories and the UK for CannEpil®, used to treat Drug-Resistant Epilepsy, and CogniCann®, used to treat patients with Dementia and Alzheimer’s disease. Sciensus Rare is an international pharmaceutical company based in the Netherlands, specializing in the provision of rare disease medicines through decentralized clinical trials and medical early access programs, with over 30-year of experience in providing health care services, and expanding medical access for products in Western Europe.
WCSC, Live 5 News, The Lowcountry’s News Leader – Live5News.com, 04/04/2022 20:00:00